Waters Stock Price, News & Analysis

Waters Corporation (NYSE:WAT) said CEO Udit Batra, Ph.D. will take part in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 2:30 PM GMT (9:30 AM ET).

A live webcast will be available on the company's Events & Presentations investor relations site (https://ir.waters.com) and a replay will be posted for 90 days. Waters is described as a global leader in analytical instruments, separations technologies, and software, operating in over 100 countries with more than 7,600 employees and over 65 years of history.

Waters (NYSE:WAT) launched a Charged Aerosol Detector (CAD) designed for native integration with Empower chromatography data system on Nov 11, 2025. The product targets Quality Control and Development labs, addressing reported CDS communication errors in up to 70% of multi-vendor LC-CAD setups and leveraging Empower, which is used to submit data for ~80% of novel drugs. The CAD promises broad analyte detection (sugars, lipids, excipients), compatibility with Waters LC systems and MaxPeak surfaces, pre-order availability now, and shipments by April 2026.

Waters (NYSE: WAT) reported third quarter 2025 sales of $800 million, up 8% as reported and in constant currency versus Q3 2024. GAAP diluted EPS was $2.50; non-GAAP EPS rose 16% to $3.40. Instruments grew 6% in constant currency; recurring revenue grew 9% CC and Pharma sales grew 11% CC. The company raised full‑year 2025 constant currency sales guidance to +6.7%–+7.3% and raised full‑year non‑GAAP EPS guidance to $13.05–$13.15 (≈+10%–+12%). Q4 2025 non‑GAAP EPS is expected at $4.45–$4.55. A conference call and webcast were scheduled for November 4, 2025.

Waters (NYSE: WAT) launched the Xevo Charge Detection Mass Spectrometer (CDMS) on Oct 13, 2025, a system for direct mass measurement of mega-mass biomolecules up to 150+ MDa. The system distinguishes empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample and operates at concentrations as low as 1×10¹⁰ vp/mL. Xevo CDMS requires up to 100-fold less sample volume than current techniques and removes the need for deconvolution or digestion. Built around an Electrostatic Linear Ion Trap (ELIT), the tech originated at Indiana University and was acquired by Waters in 2022. The system is GxP-ready with waters_connect software and is available to order now.

Waters Corporation (NYSE:WAT), a global leader in analytical instruments and technologies, has scheduled its Q3 2025 earnings conference call for Tuesday, November 4th, 2025, at 8:00 a.m. Eastern Time.

The company will host a live webcast of the presentation through its investor relations website at ir.waters.com, with a replay available until December 2nd, 2025. Waters Corporation serves the life, materials, food, and environmental sciences sectors with over 7,600 employees operating across more than 100 countries.

Waters Corporation (NYSE:WAT), a global leader in analytical instruments and technologies, announced that CEO Udit Batra, Ph.D. will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 4th, 2025, at 9:30 AM ET.

The company, which serves life, materials, food, and environmental sciences sectors, employs over 7,600 people across 100+ countries. A live webcast will be available on Waters' investor relations website, with replay access for 90 days.

Waters Corporation (NYSE:WAT) reported strong Q2 2025 financial results, with sales reaching $771 million, representing a 9% increase as reported and 8% in constant currency. The company achieved GAAP EPS of $2.47 and non-GAAP EPS of $2.95, exceeding guidance expectations.

Key performance highlights include mid-single-digit instrument growth led by LC and MS segments, and an 11% constant currency growth in recurring revenue. Pharma segment grew 11%, Industrial increased 6%, while Academic & Government declined 3%. Based on strong performance, Waters raised its full-year 2025 guidance, projecting constant currency sales growth of 5.5% to 7.5% and non-GAAP EPS of $12.95 to $13.05.

Waters (NYSE:WAT) and BD have announced a transformative $17.5 billion merger combining BD's Biosciences & Diagnostic Solutions business with Waters through a tax-efficient Reverse Morris Trust transaction. The deal will create a leading life science and diagnostics company with expected 2025 pro forma sales of $6.5 billion and adjusted EBITDA of $2.0 billion.

The merger doubles Waters' total addressable market to $40 billion and increases annual recurring revenue to over 70%. The combined entity expects $345 million in annualized EBITDA synergies by 2030, including $200 million in cost synergies by year three and $290 million in revenue synergies by year five. The transaction is expected to be accretive to adjusted EPS in the first year.

Post-merger, Waters' CEO Udit Batra will lead the combined company, which will maintain the Waters name and NYSE:WAT listing. BD shareholders will own 39.2% of the combined company, while Waters shareholders will retain 60.8%. The deal is expected to close around Q1 2026.

Waters Corporation (NYSE:WAT), a global leader in analytical instruments and technologies, has scheduled its Q2 2025 earnings conference call for Monday, August 4th, 2025, at 8:00 a.m. Eastern Time. The presentation will be accessible through a live webcast on the company's investor relations website.

The webcast replay will remain available until September 2nd, 2025. Waters Corporation serves life, materials, food, and environmental sciences sectors with over 7,600 employees operating in more than 100 countries, focusing on medicine efficacy, food safety, water purity, and product quality.